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Brief Report
ABSTRACT
We investigated the NPM1 mutation status or subcellular expression of NPM protein (nuclear vs. aberrant cytoplasmic) at diagnosis and
relapse in 125 patients with acute myeloid leukemia from Italy and Germany.All 52 patients with acute myeloidleukemia carrying at diag-
nosis mutated or cytoplasmic NPM (NPMc+ acute myeloid leukemia) retained this feature at relapse. Notably, cytoplasmic mutated NPM
has now been retained for eight years in a xenotransplant model of NPMc+ acute myeloid leukemia in immunodeficient mice. None of
73 acute myeloid leukemia  patients carrying at diagnosis wild-type NPM1 gene or showing at immunohistochemistry nucleus-restrict-
ed expression of nucleophosmin (NPMc— acute myeloid leukemia), which is predictive of NPM1 gene in germline configuration, acquired
cytoplasmic mutated NPM at relapse. This finding further confirms that NPMc+ acute myeloid leukemia represents a primary event rather
than a transformation stage of NPMc— acute myeloid leukemia. The stability of cytoplasmic mutated NPM in patients with acute myeloid
leukemia, even at relapse in extramedullary sites, and in a xenotransplant model, suggest this event is crucial for leukemogenesis and
represents the rationale for monitoring minimal residual disease and molecular targeted therapy in NPMc+ acute myeloid leukemia.
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Introduction
Nucleophosmin (NPM1) gene mutations represent the most
common genetic alteration in adult acute myeloid leukemia
(AML), accounting for about one-third of cases and 50-60% of
AML with normal karyotype.1 AML carrying NPM1 mutations
is characterized by aberrant cytoplasmic expression of nucleo-
phosmin in the cytoplasm of leukemic cells1,2 (hence the term
NPMc+ AML), and shows distinctive biological, clinical and
prognostic features,3,4 as well as a unique gene expression5 and
microRNA6 profile. Over the past two years, much information
has become available on the molecular heterogeneity of NPM1
mutations (with identification of about 40 variants to date),3 and
the structural and functional properties of encoded NPM
leukemic mutants in AML at  diagnosis.3,4 However, little is
known about  NPM1 gene status during the course of AML.7,8
Data on NPM1 gene mutation status during disease mainly
come from Asian AML patients7,8 and, because of ethnic differ-
ences, may not be suitable for extrapolation to AML in Western
countries. The recent report of  NPM1 stability in AML samples
from Italy9 does not conclusively answer this question, because
of the small number of patients investigated. Furthermore, none
of these studies provided information on the status of nucle-
ophosmin expression and nucleo-cytoplasmic transport during
the course of AML.  
To address these issues, after selecting a series of 125 AML
from Germany and Italy as representative of patients from
Western countries, we investigated  NPM1 mutation status and
subcellular NPM expression at diagnosis and relapse, using
either molecular analysis or immunohistochemistry. We also
used a xenotransplant model of NPMc+ AML in immunodefi-
cient mice to investigate the status of the NPM1 gene and pro-
tein over an extensive period of time.
Design and Methods
Leukemic samples
Bone marrow biopsies for immunohistochemical studies at
diagnosis and relapse were obtained from 47 AML patients fol-
lowed at the Institutes of Hematology, Universities of Perugia
and Rome (“La Sapienza”). NPM1 mutation status was analyzed
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at diagnosis and relapse in bone marrow leukemic cells
from 78 AML patients collected at the Munich Leukemia
Laboratory (MLL). All AML cases from Munich carried a
normal karyotype and this allowed us to investigate the
status of NPM1 in the context of this cytogenetic catego-
ry. Cytogenetics and/or molecular analysis for the major
recurrent genetic abnormalities were available in 33 out of
47 AML patients from Perugia and Rome  (17 out of 23
NPM1-mutated and 16 out of 24 NPM1-unmutated).
Sixteen out of the 17 NPM1-mutated AML cases showed
a normal karyotype and one case carried a secondary chro-
mosomal aberration (+8). Three out of the 16 NPM1-
unmutated AML cases carried a normal karyotype while
the remaining 13 cases showed the following chromoso-
mal abnormalities: t(8;21)/AML1-ETO (n=2);
t(15;17)/PML-RARα (n=2); t(6;11) (n=1); t(6;9)/DEK-CAN
(n=1); t(1;3) (n=1); t(3;5) (q21;q31)/NPM-MLF1 (n=1);
del(9q) (n=1); monosomy 7 (n=2); iso17q (n=1) and a com-
plex karyotype (n=1).  
Immunohistochemical studies
NPM subcellular expression was detected in paraffin-
sections from B5-fixed/EDTA decalcified bone marrow
trephines or formalin-fixed extramedullary bioptic sam-
ples (n=5 myeloid sarcomas) using anti-NPM specific anti-
bodies and the highly sensitive alkaline phosphatase anti-
alkaline phosphatase (APAAP) technique, as previously
described.1 The rationale for this approach derives from
our previous observations that immunohistochemistry is
fully predictive of NPM1 mutation status.10 In fact, cases of
AML with aberrant NPM cytoplasmic expression (NPMc+)
always carry NPM1 mutations, while cases showing
nucleus-restricted NPM positivity (NPMc– AML) consis-
tently harbor a wild-type NPM1 gene. 
Mutational analysis of the NPM1 gene
Mononucleated cells were isolated by standard Ficoll-
Hypaque density gradient centrifugation. Nucleic acid iso-
lation, cDNA synthesis and screening for NPM1 gene
mutations were performed using a melting curve-based
LightCycler assay, as previously described.11 AML samples
with an aberrant melting curve underwent nucleotide
sequence analysis. 
Western blot analysis
NPM mutant protein expression was detected by
Western Blot analysis on whole cell lysates of NPMc+ AML
cells from xenotransplanted mice (see below) using an
affinity-purified rabbit polyclonal antibody (anti-NPMm,
Sil-A), which specifically recognizes the NPM leukemic
mutant protein, as previously described.12
Establishment of human NPMc+ AML xenografts in
immunodeficient mice 
Xenotransplant of NPMc+ AML in immunodeficient
mice was established from the leukemic cells of a 36-year-
old female (M.A.) with AML-M4 carrying cytoplasmic
mutated NPM (mutation A). Besides NPM1 mutation, the
leukemic cells harbored FLT3 internal tandem duplication
(FLT3-ITD). The disease was resistant to treatment, even
after a haploidentical peripheral blood stem cell transplant
performed at the Hematology Institute, Perugia
University, in April 1999. When the patient relapsed (July
1999), bone marrow leukemic cells were isolated by stan-
dard Ficoll-Hypaque density gradient centrifugation and
used to inject mice. Five  4-6 week old C.B-17 SCID/SCID
non-irradiated mice were injected subcutaneously in the
flank with between 50 and 100×106 NPMc+ leukemic cells.
Injected cells produced palpable tumors in all mice by 3-4
weeks. The presence of cytoplasmic mutated NPM at the
first and second passage proved that xenograft tumors
were derived from the patient’s  leukemic sample. To
propagate xenografts, tumors were removed, minced in
Dulbecco’s phosphate buffered saline (D-PBS) and re-
injected subcutaneously into immunodeficient mice. The
NPM1 gene and protein status of xenografted NPMc+
AML tumors was investigated at established time-points
using molecular techniques,  immunohistochemistry and
Western blot analysis. 
Results and Discussion
The results of  immunohistochemical studies on bone
marrow and extramedullary  site biopsies in Italian AML
patients are shown in Table 1 and Figure 1. All 24 NPMc+
AML cases with aberrant cytoplasmic NPM expression at
diagnosis retained this abnormal staining pattern at
relapse (Figure 1). The percentage of NPMc+ leukemic
cells and the intensity of NPM cytoplasmic positivity
were usually the same at first diagnosis and relapse (data
not shown). 
In cases of early relapse, small clusters of re-emerging
NPMc+ leukemic blasts co-existed with a population of
normal hemopoietic cells showing nucleus-restricted
NPM expression (Figure 1, top left and right).
Conversely, none of the 24 AML cases with nucleus-
restricted NPM positivity (which is predictive of NPM1
gene in a germline configuration) at diagnosis showed
cytoplasmic NPM expression at relapse (data not shown).
All AML relapsing as myeloid sarcoma retained, even in
extranodal sites, the same NPM staining pattern as at
diagnosis (nucleus-restricted or cytoplasmic) (Figure 1,
bottom left and right). Molecular investigations into
NPM1 mutation status at diagnosis and relapse in
German patients with AML provided identical results
(Table 1). At relapse, all cases showed  the  same NPM1
mutation as found at diagnosis.
The time lapse between diagnosis and relapse in AML
is usually very short (median one year), which raises the
question of whether patients were observed for  enough
time to detect changes in NPM1 mutation status and
NPM protein expression. Our xenotransplant model of
NPMc+ AML in SCID mice provides evidence of NPM1
mutation stability and aberrant cytoplasmic expression
of NPM over time, and indicates they are intrinsic fea-
tures of the leukemic process. At present (2007), after 53
passages, NPMc+ AML cells from patient M.A. (Figure 2,
top left) that were xenografted into SCID mice in 1999
still maintain their original features. Engraftment  occurs
in 100% of animals and subcutaneous tumors develop in
3-4 weeks, usually remaining outside the abdominal fas-
cia (data not shown). The morphology and phenotype
(expression of myeloperoxidase and macrophage-
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restricted CD68) of the subcutaneously growing
leukemic cells appear the same as the patient’s myelo-
monocytic blasts (Figure 2, top left). Most importantly,
they show the same biological features as the patient’s
leukemic cells, i.e i) aberrant cytoplasmic expression of
NPM (Figure 2, middle left), but nucleus-restricted posi-
tivity for C23/nucleolin (Figure 2, middle right); and ii)
presence of a mutated NPM protein (Figure 2, bottom)
and NPM1 mutation A (data not shown).
Evidence that the stability of mutated NPM1 gene and
protein persists over a long period of time also comes from
other sources. We previously reported a case of  NPMc+
myeloid sarcoma 20 years after diagnosis of AML.13
Furthermore, the OCI-AML3  cell line, which was gener-
ated in 1989 from a 57 year-old male  with AML FAB-M4
(karyotype not established),14 harbors two distinguishing
characteristics of NPMc+ AML., i.e. NPM1 mutation A and
aberrant cytoplasmic expression of NPM.12
The results presented in this paper have important bio-
Mutated nucleophosmin in AML
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Figure 1. Medullary and extramedullary relapse of NPMc+ AML. Top, left. Early bone marrow relapse by NPMc+ AML. Clusters of NPM
cytoplasmic positive blasts co-exist with normal hemopoietic cells with nucleus-restricted positivity (double arrows point to a normal
megakaryocyte); T indicates a bone trabecula (Bone marrow trephine; APAAP technique; ×400). Top right. Higher magnification from a
different field of the bone marrow biopsy. The single arrows indicate AML cells with aberrant cytoplasmic expression of NPM, while the
double arrows point to a normal hemopoietic cell (Bone marrow trephine; paraffin section; APAAP technique; ×800). Bottom, left. Partial
infiltration of the lymph node by myeloid leukemic cells showing aberrant cytoplasmic expression of nucleophosmin (upper right area).
Residual lymphoid elements exhibit the expected nucleus-restricted NPM positivity (lower left area). C. Indicates the lymph node cap-
sule (lymph node paraffin section; APAAP technique; ×400). Bottom, right. Higher magnification from a different field of the lymph node
showing aberrant expression of NPM in the cytoplasm of leukemic cells (arrows). The double arrows point to a residual lymphoid cell
with NPM positivity restricted to the nucleus (lymph node paraffin section; APAAP technique; ×800).
Table 1. Cytoplasmic mutated nucleophosmin in 125 cases of
acute myeloid leukemia at diagnosis and relapse.
NPM mutations/expression#
AML (N.) Diagnosis Relapse 1 Relapse 2
Perugia
20* Nuclear Nuclear
3 Nuclear Nuclear Nuclear
23° Cytoplasmic Cytoplasmic
1 Cytoplasmic Cytoplasmic Cytoplasmic
Munich
41 Unmutated Unmutated
9 Unmutated Unmutated Unmutated
26 Mutated Mutated
2 Mutated Mutated Mutated
*In 2 cases relapse was at bone marrow and extramedullary sites; °in 3 cases
relapse was at bone marrow and extramedullary sites; #nuclear expression of
NPM indicates unmutated NPM1, cytoplasmic expression of NPM indicates
mutated NPM1.
logical and clinical implications. The inability of AML
with a normal karyotype to transform from a NPMc– to a
NPMc+ status reinforces the concept that NPMc+ AML rep-
resents a clearly distinct entity and it is not a transforma-
tion stage of NPMc– AML. This was also shown by gene
expression profile analysis.5,15 This finding, together with
the observation that cytoplasmic mutated NPM is stable in
AML patients and in a xenotransplant model of NPMc+
AML, suggests NPM1 mutations are a founder genetic
lesion in AML. This view is also in agreement with previ-
ous findings that NPM1 mutations are mutually exclusive
with other recurrent genetic abnormalities.16 In addition,
our immunohistochemical studies show that, during dis-
ease evolution, NPM1 mutated genes efficiently continue
to encode NPM mutated proteins which are aberrantly
exported from nucleus to cytoplasm. Accumulation of
NPM mutants  in leukemic cell cytoplasm at relapse, even
at extramedullary sites, strongly suggests  cytoplasmic dis-
location plays a crucial role in leukemogenesis. This view
is also supported by our findings that NPM1 mutations
aim to achieve massive exportation of leukemic mutants
from the nucleus (with consequent accumulation in the
cytoplasm) by using different strength C-terminus NES
motifs.17 Notably, this phenomenon also occurs with very
rare mutations that involve exon-918 and exon-1119-21 of the
NPM1 gene. Furthermore, we recently showed that, in
human genome, the generation of a nuclear export signal
through duplication appears unique to NPM1 mutations
and is restricted to AML.22
Demonstrating that NPM1 mutations are stable in AML
patients not only from Asia but also from Western coun-
tries provides a rationale for widespread minimal residual
disease monitoring in NPMc+ AML  by means of  quanti-
tative PCR assessment of NPM1 mutant transcripts.23
Results appeared predictive of early relapse and long-term
prognosis in patients from Taiwan,24 and preliminary
observations from the Munich Leukemia Laboratory indi-
cate the approach is feasible in patients from Western
countries (Schnittger S. et al., manuscript in preparation). 
Finally, finding that leukemic cells exhibit aberrant NPM
cytoplasmic expression at all disease stages provides a
rationale for developing drugs designed to interfere with
this abnormal NPM nucleo-cytoplasmic traffic and re-
direct the protein to the nucleolus, its physiological site.25
In this regard, our xenograft model for human NPMc+
AML may, in combination with the OCI-AML3 cell line,12
serve as a valuable pre-clinical in vivo assay for the devel-
opment of new anti-leukemic drugs.
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Figure 2. Xenotransplantation
model of NPMc+ AML in SCID
mice.  Top, left. Bone marrow
biopsy from patient M.A. at the
time of relapse (June 1999).
Leukemic cells show aberrant
cytoplasmic expression of nucle-
ophosmin which is indicative of
NPM1 mutation (APAAP tech-
nique; ×200); T indicates a bone
trabecula. Inset: leukemic cells at
higher magnification (×800). Top,
right. Leukemic cells from the
NPMc+ AML patient M.A. growing
as subcutaneous mass in the
mouse right flank (arrow). The
tumor cells show aberrant cyto-
plasmic expression of NPM (mid-
dle, left) and nucleus-restricted
positivity for C23/nucleolin (mid-
dle, right) (paraffin sections from
a tumor mass at the 53rd passage
in mice; ×800); the arrow in panel
middle-right indicates a mitotic
figure. Bottom, left. Leukemic
cells from the mass at the 53rd
passage in mice showing a myelo
monocytic appearance (imprint of
the mass; May-Grünwald-GIemsa;
×800). Bottom, right. Western
blotting showing the presence of
a mutated NPM protein in lysates
from leukemic cells at the 53rd
passage in mice. A clear band at
37 kDa molecular weight corre-
sponding to NPM mutant protein
is evident in whole cell lysate
from mice tumor mass cells (lane
1). The OCI/AML3 cell line and an
NPMc+ AML patient (lane 2) are
included here as positive controls
for expression of NPM mutant
protein. Negative controls are rep-
resented by cells from two NPMc–
AML patients (lanes 3 and 4). 
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